#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia

Experience shows that monitoring joint changes, especially subclinical ones, is very necessary in the care of hemophiliacs. Unfortunately, conventional X-rays cannot detect early changes in joints. Magnetic resonance imaging (MRI) plays an indispensable role in detecting these changes.
Source: Hemophilia 16. 3. 2020

News Type of Pharmacological Thromboprophylaxis and Disease Stage as Risk Factors for Bleeding in Patients After Colorectal Cancer Surgery

Japanese authors of a study published last year in the World Journal of Surgical Oncology attempted to answer the question of whether the incidence of postoperative bleeding in patients undergoing elective surgery for colorectal cancer is associated with the type of pharmacological prophylaxis or the disease stage.
Source: Thromboprophylaxis 14. 3. 2020

News Direct Comparison of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis

The final results of the direct comparison of ixekizumab and adalimumab in the therapy of biologic-naïve patients with psoriatic arthritis were presented at the annual conference of the American College of Rheumatology (ACR/ARP) in November 2019 in Atlanta.
Source: Biological Treatment 6. 4. 2020

News Efficacy and Safety of Soybean and Avocado Unsaponifiables in the Treatment of Knee and Hip Osteoarthritis

Osteoarthritis represents a chronic irreversible degenerative joint disease, the prevalence of which increases with age. Various approaches are applied in therapy, including the administration of preparations aimed at reducing symptoms of the disease and slowing its progression. A recently published study provides current insights into the efficacy and safety of unsaponifiable soybean and avocado oil in the treatment of hip and knee osteoarthritis.
Source: Osteoarthritis Therapy 4. 4. 2020

News Forgotten Pulmonologists: COVID-19 Detection in Patients with Lung Disease

The Czech Pneumological and Phthisiological Society of ČLS JEP (ČPFS) submitted a request to the Ministry of Health of the Czech Republic on March 25, 2020, to allow pulmonologists to send patients with suspected COVID-19 directly for infection testing. In their statement, they also provide recommendations on how to manage care for patients with chronic lung diseases during the outbreak of the SARS-CoV-2 virus and how these patients should behave.
Source: Asthma under control 7. 4. 2020

News Prevalence of Diabetics Among Patients with COVID-19 and the Impact of DM on the Course of Infection

Italian authors published the results of a meta-analysis of studies at the end of March, assessing the prevalence of diabetes among individuals infected with SARS-CoV2 and the impact of diabetes on the severity and progression of the infection.
Source: Modern Treatment of Diabetes 14. 4. 2020

News Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype

A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in chronic lymphocytic leukemia (CLL). An analysis of the impact of complex karyotype on the efficacy of targeted CLL therapy combining the monoclonal antibody against CD20 antigen obinutuzumab with the BCL2 inhibitor venetoclax or the alkylating cytostatic chlorambucil was published in the journal Blood.
Source: Chronic Lymphocytic Leukemia 22. 4. 2020

News Obinutuzumab and Early Progression of Patients with Previously Untreated Follicular Lymphoma − Analysis of Data from the GALLIUM Study

The GALLIUM study demonstrated longer progression-free survival (PFS) in patients with previously untreated follicular lymphoma (FL) treated with obinutuzumab compared to rituximab. The aim of the exploratory data analysis was to evaluate the impact of obinutuzumab on the incidence of early disease progression and the relationship between early progression and overall survival (OS) of the patients.
Source: Non-Hodgkin Lymphomas and CLL 23. 4. 2020

News Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis

Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in the Czech Republic for the treatment of active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis. Its efficacy compared to adalimumab in PsA was evaluated in the head-to-head SPIRIT-H2H study. A post-hoc analysis of this study focusing on a subpopulation of patients with PsA and concurrent moderate to severe plaque psoriasis was presented at the Congress of the European Academy of Dermatology and Venereology (EADV) in October 2019 in Madrid.
Source: Biological Treatment 9. 5. 2020

News L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section

The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and Nutrition focused on comparing the effect of infant formula containing Lactobacillus reuteri DSM 17938 on the microbiota of children born by cesarean section or vaginal delivery.
Source: GI, colic and microbiome 15. 5. 2020

News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis

Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.
Source: Biological Treatment 19. 5. 2020

News Targeted DNA Sequencing Helps Find Targeted Therapy for Patients with NSCLC

Gene sequencing has become a key tool in deciding the treatment for patients with non-small cell lung cancer (NSCLC). At a university in Seoul, South Korea, a retrospective analysis of the benefits of targeted genetic testing in real clinical practice was conducted.
Source: Genetic Profile and Treatment of NSCLC 25. 5. 2020

News Comparison of the Efficacy and Safety of Two Enoxaparin Dosing Regimens in Patients After Chest Surgery

Effective prevention of thromboembolic disease in patients undergoing chest surgery is one of the key therapeutic goals. However, the question remains as to what dose of low molecular weight heparin is optimal for these individuals. A multicenter clinical trial compared the efficacy of a fixed dose of enoxaparin to a weight-adjusted dose.
Source: Thromboprophylaxis 31. 8. 2020

News Thromboprophylaxis in Cancer Patients − Results of Current Meta-Analysis

A recently published meta-analysis shows the benefits of thromboprophylaxis in cancer patients, with no increased risk of severe bleeding complications.
Source: Thromboprophylaxis 27. 5. 2020

News Empagliflozin in the Treatment of Patients with Chronic Heart Failure

Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.
Source: Heart Failure 7. 12. 2021

News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC

Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.
Source: Genetic Profile and Treatment of NSCLC 23. 7. 2021

News Perioperative substitution therapy in patients with vWD must be tailored

Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.
Source: Von Willebrand Disease 25. 8. 2021

News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease

A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).
Source: Von Willebrand Disease 25. 8. 2021

News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia

An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.
Source: Modern Treatment of Schizophrenia 18. 5. 2021

News Can sartans improve clinical outcomes in hypertensive patients with COVID-19?

Dysfunction of the renin-angiotensin system (RAS) has been detected in patients with COVID-19. This finding led to the hypothesis that RAS inhibitors (RASi) could help these patients. To verify this, a retrospective study was conducted, the results of which we briefly summarize.
Source: Sartans in the Treatment of Hypertension 19. 4. 2021

News Role and Possibilities of Telemedicine in the Management of Hemophilia Care

A team of Irish experts recently evaluated the current possibilities of telemedicine in the care of individuals with hemophilia – not only from the perspective of care provided by specialized comprehensive centers but also considering physiotherapy and dental care.
Source: Hemophilia with Movement 22. 4. 2021

News Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?

The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study investigated whether the renal function of patients affects the extent of the reversing effect of idarucizumab on the effect of dabigatran.
Source: Anticoagulant Treatment 29. 3. 2021

News New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan

The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its potential use in the treatment sequence of metastatic pancreatic ductal adenocarcinoma.
Source: Treatment of Gastrointestinal Carcinomas 11. 5. 2021

News Sport as an Important Part of the Life of Hemophiliacs

People with congenital bleeding disorders have very diverse approaches to sports and exercise. The possibility of preventing bleeding by administering safe and effective medications for these patients clearly supports engagement in an active physical life.
Source: Hemophilia with Movement 7. 4. 2021

News Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?

In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral anticoagulants were published. This involved 14 patients with atrial fibrillation and HIV infection, in whom the concurrent administration of dabigatran with antiretroviral drugs was not associated with the occurrence of thromboembolic events or bleeding during follow-up lasting up to 40 months.
Source: Anticoagulant Treatment 6. 5. 2021

1 2 3 4 5 6 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#